NeuroBionics
Ross Tsukashima serves as the Head of Innovation at NeuroBionics since January 2025, focusing on advanced neural interface technology. As the Founder and CEO of Sensoria Therapeutics, Inc. since February 2021, Ross leads the development of innovative minimally invasive medical devices for diagnosing and treating neurological diseases. Prior experience includes roles as Head of Scientific Research & Development at Integra LifeSciences and Chief Scientific Officer at Rebound Therapeutics, where responsibilities encompassed optical design and system integration for medical technologies. Ross also directed engineering for implanted ophthalmology devices at Revision Optics, contributing to the FDA approval of a corneal implant. Educational background includes studies at California State University, Long Beach.
This person is not in any teams
This person is not in any offices
NeuroBionics
NeuroBionics is pioneering the future of precision bioelectronic medicine by developing the next generation of implantable devices, designed to seamlessly interface with the human body. Our core technology lies in flexible, multifunctional fibers the size of a human hair, which can record and stimulate neural activity, deliver drugs, and ablate tissue. Using an endovascular approach, we will navigate our microscopic-sized flexible fiber implant through the intricate network of blood vessels to deliver precise therapeutic intervention to neural tissue. By making neural interfacing a minimally-invasive procedure, we will revolutionize deep brain stimulation and broaden access to this lifechanging therapy. By doing so, we aim to improve the lives of millions grappling with conditions like Parkinson's disease, essential tremor, epilepsy, and depression.